{"id":"W2946105917","doi":"10.1093/eurheartj/ehz299","title":"Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta; St. Michael's Hospital","funders":"American Regent; Genentech; Esperion Therapeutics; Idorsia Pharmaceuticals; Duke Clinical Research Institute; Astellas Pharma; Eisai; Bayer HealthCare; Medicines Company; Regado Biosciences; Verily Life Sciences; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; St. Jude Medical; Flatiron Health; Green Lane Research and Educational Fund; Regeneron Pharmaceuticals; Abbott Vascular; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; Belvoir Media Group; Novo Nordisk; MyoKardia; Janssen Pharmaceuticals; Ablynx; Daiichi Sankyo Europe; Servier; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Sanofi; American Heart Association","keywords":"Medicine; Alirocumab; Myocardial infarction; Cardiology; Internal medicine; PCSK9; Intensive care medicine; Cholesterol; Lipoprotein; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00230442,0.0006954711,0.001488694,0.0002070902,0.0002837716,0.0008757656,0.0004487793,0.0006459671,0.001823338],"category_scores_gemma":[0.004066353,0.0001920251,0.001570138,0.0002950457,0.0003484325,0.0005950037,0.0008560185,0.001189772,0.0001331046],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004335608,"about_ca_system_score_gemma":0.0004937709,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001845669,"about_ca_topic_score_gemma":0.004475829,"domain_scores_codex":[0.9988625,0.0006682923,0.00009116993,0.0001547828,0.000105114,0.0001180849],"domain_scores_gemma":[0.9978068,0.0006004978,0.0008434894,0.000180697,0.0001487078,0.0004198135],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7306469,0.003820335,0.1461592,0.003269302,0.02167707,0.0001956974,0.0002610977,0.001155987,0.001499659,0.0006988869,0.006281929,0.084334],"study_design_scores_gemma":[0.2563167,0.03258124,0.6729668,0.0009014801,0.0241777,0.000489659,0.0002826148,0.003229581,0.0009776626,0.001949902,0.006011661,0.000115047],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775835,0.01675866,0.0002296899,0.001013131,0.0001512771,0.0001784969,0.001660403,0.00002530299,0.002399502],"genre_scores_gemma":[0.9940352,0.00271407,0.0003460218,0.0006296561,0.0001941841,0.0001699187,0.001392917,0.000005454647,0.0005125178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00230442,"threshold_uncertainty_score":0.01218706,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01707089362362753,"score_gpt":0.2683105716992243,"score_spread":0.2512396780755968,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}